AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging

AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging eurekalert.org